Newly activated UI Cancer Center Clinical Trials

The following studies have recently been activated for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office (CTO). Please click on the link to learn about the details regarding the study on For more information or questions about a study, please email or call 312-355-5112.

INCB53914-102: A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Sponsor: Incyte Corporation
Principal Investigator: John Galvin, MD

BTCRC AML17-113: Phase 1b Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia

Sponsor: Big Ten Cancer Research Consortium
Principal Investigator: John Quigley, MD

Translate »